Microbix Partners with EMQN for EQA Program
Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF), a leader in life sciences, is collaborating with EMQN CIC to introduce a transformative program designed to enhance the accuracy of genetic testing related to hearing loss susceptibility in patients treated with commonly prescribed antibiotics.
Addressing Critical Health Concerns
This groundbreaking External Quality Assessment (EQA) program aims to ensure laboratories can effectively identify patients carrying the MT-RNR1 m.1555A>G gene variant. This genetic variation affects individuals' susceptibility to significant hearing loss when exposed to aminoglycoside antibiotics, which are frequently used to combat severe infections.
With one in 500 individuals affected by this variant, recognizing it in a timely fashion becomes essential, particularly for at-risk populations like newborns. Without appropriate interventions, these at-risk patients could face severe consequences, including irreversible hearing impairment.
Innovative Quality Assessment Products
Microbix's quality assessment products (QAPs™) are integral components of the EMQN EQA program. Designed for use with Copan® FLOQSwabs®, these products enable labs to simulate real testing conditions by processing samples akin to buccal swabs.
Regular Proficiency Testing
Participating laboratories will receive three testing samples bi-monthly, allowing them to continuously gauge the proficiency and accuracy of their assessments. This rigorous approach ensures that healthcare providers can reliably diagnose and treat patients, ultimately improving clinical outcomes.
Sean Sales, Operations Director at EMQN, highlighted the importance of this partnership, stating that the initiative equips healthcare professionals with vital information, assisting them in making informed decisions regarding antibiotic use and minimizing the risk of lifelong hearing loss.
Microbix's Commitment to Accurate Testing
Cameron Groome, CEO of Microbix, expressed enthusiasm about the partnership, emphasizing the significance of this EQA program in improving genetic testing. This initiative represents Microbix's strategic expansion into supporting the accuracy of genetic assessments, building upon its established expertise in infectious diseases and emerging oncology applications.
Joining Forces for Better Health Outcomes
The collaboration between Microbix and EMQN enables labs to reaffirm their testing accuracy, which is crucial for precise patient diagnosis and care, especially in acute medical situations.
Laboratories interested in enrolling in this innovative program can connect with EMQN to gain crucial insights and tools to enhance their diagnostic capabilities, contributing to safer treatment practices.
About Microbix Biosystems Inc.
Microbix Biosystems Inc. is known for developing proprietary biological products that serve the global health landscape. With a robust workforce exceeding 100 professionals, Microbix is on a trajectory to generate sales that target C$ 2 million monthly. By providing critical ingredients and devices to the diagnostics sector, the company plays a pivotal role in ensuring high-quality healthcare delivery.
Microbix's market offerings include antigens utilized in immunoassay tests and their flagship laboratory quality assessment products (QAPs™). These products not only bolster lab proficiency but also support diagnostic validation efforts, essential in maintaining the integrity of clinical workflows.
About EMQN CIC
Based in Manchester, EMQN CIC is dedicated to elevating the standard of laboratory practices in genetic testing. Their EQA schemes are pivotal in maintaining the highest quality of molecular diagnostics. As an accredited body, EMQN periodically publishes guidelines and best practices to ensure laboratories are performing at their best, a critical function for the ongoing improvement of diagnostic accuracy.
Frequently Asked Questions
What is the aim of the EQA program launched by Microbix and EMQN?
The EQA program is designed to enhance the accuracy of genetic testing for patients at risk of hearing loss due to specific antibiotic treatments.
How does Microbix contribute to this program?
Microbix provides quality assessment products (QAPs™) which help laboratories verify their testing methods and ensure diagnostic reliability.
Why is early identification of the MT-RNR1 variant crucial?
Identifying the variant early can prevent the onset of potentially irreversible hearing loss, particularly in vulnerable populations such as newborns.
How frequently do participants receive testing samples?
Participants receive three testing samples every two months, totalling 18 samples per year, to ensure continuous proficiency assessment.
In which sectors does Microbix operate?
Microbix specializes in developing products for infectious diseases and oncology, with a strong focus on supporting the precision of genetic testing and diagnostics.
